Mendus to participate in investor and industry conferences in March
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:
Dutch ATMP Summit
Leiden, The Netherlands, March 12, 2025
Director CMC Anneke Reurs will participate and NorthX Biologics’ CEO Janet Hoogstraate will present the progress of the large-scale manufacturing alliance with Mendus in a presentation titled “How to set-up the GMP production of a cell therapy for Acute Myeloid Leukemia (AML) including automation in manufacturing, QC & release testing” at 13.15 CET
For more information, please see Dutch ATMP Summit
NextGen Biomed
London, United Kingdom, March 12 – 14, 2025
Director Immune and Disease Monitoring Hester van Zeeburg will participate as speaker and discussion panel member and hold a presentation titled “Active immunotherapy in AML” on March 13, 9.50 GMT
For more information, please see NextGen Biomed 2025
BIO Europe Spring
Milan, Italy, March 17 - 19, 2025
CEO Erik Manting will participate for industry and investor meetings.
For more information, please see BIO Europe Spring 2025
Advanced Therapies Europe 2025
London, United Kingdom, March 18 -19, 2025
CMO Jeroen Rovers and Head of Regulatory Affairs Anna Koptina will participate as speakers and discussion panel members. Anna Koptina will hold a presentation titled “The latest developments in regulation for Advanced Therapy Medicinal Products” on March 19, 11.40 GMT. Jeroen Rovers will hold a presentation titled “Development of an active immunotherapy as maintenance treatment for acute myeloid leukemia” on March 19, 13.40 GMT
For more information, please see Advanced Therapies 2025
Immuno-Oncology 360° Summit
Boston, US, March 24 – 26, 2025
CEO Erik Manting will participate for investor and industry meetings during the 11th annual IO360° Summit, a conference dedicated to reporting on the latest advancements and data in Immuno-Oncology and present the lead program vididencel in a presentation titled “Active immunotherapy to achieve durable clinical remissions in MRD+ AML” on March 25, 16.00 ET.
For more information, please see Immuno-Oncology 360°Summit
51th annual meeting EBMT
Florence, Italy, March 30 – April 2, 2025
CMO Jeroen Rovers will participate in the 51th annual meeting of EBMT, a non-profit medical and scientific organization connecting patients, researchers and other stakeholders to anticipate the future of cellular and stem cell-based therapies.
For more information, please see 51th annual meeting EBMT